ArticleActa dermato-venereologica2022
Long-term Remission of Atopic Dermatitis after Discontinuation of Dupilumab.
Article in Acta dermato-venereologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Outcomes and Predictors of Sustained Response After Dose Tapering of Targeted Therapies in Moderate-to-Severe Atopic Dermatitis: A Systematic Review.American journal of clinical dermatology · 2026Pooled it
- Systemic Therapy for Atopic Dermatitis in Children and Adolescents: A US Expert Consensus.Dermatology (Basel, Switzerland) · 2024Guideline
- The era of advanced therapeutics for pediatric atopic dermatitis - can early systemic intervention reduce the type 2 inflammatory response and modify the atopic march?Current opinion in pediatrics · 2026Review
- Dosing Interval Extension of Dupilumab in CRSwNP: Five-Year Real World Outcomes.International forum of allergy & rhinology · 2026Article
- The Western Japan Atopic Dermatitis Registry (WJADR): A Multicenter Real-World Registry of Systemic Therapies for Atopic Dermatitis.Journal of clinical medicine · 2026Review
- Clinical remission in allergy and clinical immunology practice: State of the art and World Allergy Organization (WAO) call to action.The World Allergy Organization journal · 2026Review
- Tissue-resident memory T cells in atopic dermatitis: mechanisms of residual inflammation, relapse, and therapeutic persistence.Frontiers in immunology · 2026Review
- Interleukin-4 and Atopic Dermatitis: Why Does it Matter? A Narrative Review.Dermatology and therapy · 2025Review
- Innovations and Emerging Therapies in Atopic Dermatitis Part 1.Current treatment options in allergy · 2025Article
- The value of biomarkers in the therapy of CRSwNP with biologicals-a long-term follow-up of dupilumab therapy.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024Article
- Systemic Biologic Management of Atopic Dermatitis.Advances in experimental medicine and biology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.